Changes in Symptoms and Adverse Events after Discontinuation of Atomoxetine in Children and Adults with Attention Deficit/Hyperactivity Disorder: A Prospective, Placebo-Controlled Assessment

Journal of Clinical Psychopharmacology

Volumn 24, Issue 1, 2004, Pages 30-35

  Wernicke, Joachim F ^a   Adler, Lenard ^b   Spencer, Thomas ^c   West, Scott A ^d   Allen, Albert J ^a   Heiligenstein, John ^a   Milton, Denái ^a   Ruff, Dustin ^a   Brown, W Jeffrey ^a   Kelsey, Douglas ^a   Michelson, David ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d CNS Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; NORADRENALIN TRANSPORTER; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; FEVER; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LIMB PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; NAUSEA; NEUROTRANSMITTER RELEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SINUSITIS; SORE THROAT; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME;

EID: 9144256611     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000104907.75206.c2     Document Type: Article

References (14)

1. Schweizer E, Rickels K, Case WG, et al. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47:908-915.
2. Noyes R Jr, Garvey MJ, Cook B, et al. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry. 1991;148:517-523.
3. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363-368.
4. Michelson D, Faries DE, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.
5. Kratochvil CJ, Heiligenstein JH, Dittman R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
6. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1-6.
7. Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scale as a Clinician Administered and Scored Instrument. J Atten Disord. 2001;5:39-47.
8. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990; 86:184-192.
9. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda: Multi-Health Systems Inc., 1999.
10. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
11. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
12. The AMDP-System. Association of Methodology and Documentation in Psychiatry; Manual For the Assessment and Documentation of Psychopathology. Berlin, Springer; 1982.
13. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995;52:173-188.
14. Garland EJ. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol (Oxf). 1998;12:385-395.